Cooler Heads has closed an oversubscribed $11 million Series A funding round to expand the manufacturing and rollout of Amma™, the only FDA-cleared Portable Scalp Cooling System. The Amma™ system helps chemotherapy patients keep their hair and preserve their privacy, eliminating the disfiguring hair loss that has long been an accepted side effect of chemotherapy.

The Series A financing was led by Mutual Capital Partners, a Cleveland healthtech-focused venture capital fund, and contained participation from SHD Partners, Crescent Ridge VC, Cal Innovation Fund, NuFund, Robin Hood Ventures, Golden Seeds, HIP VC, and an unnamed strategic investor. Funds will be used to increase manufacturing capacity, expand the commercial team, and to develop the next generation of the product.

Cooler Heads provides evidence-based products, content, and services that cancer patients need to manage the challenging side effects of treatment. Founded by a cancer survivor, Cooler Heads is driven by the mission to reduce the physical and emotional toll of cancer treatment, offering tools like Amma to improve the quality of life for patients.